EHS
EHS

Treatment-as-prevention only viable with expanded HCV coverage

Results of a modeling study showed that in dense urban settings with high prevalence of hepatitis C among people who inject drugs, HCV treatment-as-prevention strategies will have little impact over 10 years unless coverage is greatly expanded.
“With the availability of more tolerable and eective direct-acting antivirals, HCV treatment-as-prevention strategies could substantially curtail HCV transmission and reduce the burden of HCV,” Alexei Zelenev, PhD, from the Yale School of Medicine in Connecticut, and colleagues wrote. “Completely eliminating HCV … will require a

Source link

EHS
Back to top button